<DOC>
	<DOCNO>NCT00568334</DOCNO>
	<brief_summary>The aim study evaluate modify formulation GSK Biologicals ' live attenuate varicella vaccine . In vivo pre-clinical data show change negative impact vaccine safety . This present study undertaken rule negative impact immunogenicity safety GSK Biologicals ' live attenuate varicella virus vaccine .</brief_summary>
	<brief_title>Study Two Formulations GSK Biologicals ' Varicella Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol ( e.g . completion diary card , return followup visit ) enrol study . A male female , include , 11 21 month age time first vaccination . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol within 30 day prior first study vaccine dose 42 day second study vaccine dose exception oral polio vaccine ( OPV ) give time routine inactivate vaccine administer eight day study vaccine dose . Previous vaccination varicella . Known history clinical varicella . Known exposure varicella within 30 day prior study start . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine ( ) , include systemic hypersensitivity neomycin . Major congenital defect serious chronic illness . Acute disease time enrolment . All vaccine administer person minor illness . Axillary temperature ≥ 37.5°C / Rectal temperature ≥ 38°C . Residence household high risk person e.g . : newborn infant ( 04 week age ) , pregnant woman negative history chickenpox , person know immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>11 Months</minimum_age>
	<maximum_age>21 Months</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>chickenpox</keyword>
	<keyword>varicella</keyword>
	<keyword>two-dose schedule</keyword>
	<keyword>second year life</keyword>
</DOC>